Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutio...( NEW YORK Jan. 7 /- Crystal Resear...),Health

NEW YORK, Jan. 7 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited (UNI-ASX). The full 72-page report can be found at www.crystalra.com and www.unilife.com.

Unilife Medical Solutions Limited ("Unilife" or "the Company") develops and supplies innovative safety medical devices to healthcare and pharmaceutical markets. Specifically, the Company is focused on targeting pharmaceutical markets for prefilled safety syringes; healthcare markets that mandate the use of sharps safety devices to prevent needlestick injuries; and the U.S. medical device contract manufacturing market. Unilife has developed a patent-protected portfolio of safety syringes, with product lines including the Unilife Ready-to-Fill Syringe ([RTFS] hereafter referred to as the Unilife Prefilled Syringe), the Unitract(TM) 1mL Insulin and Safe Syringes, and the Unitract(TM) Clinical Range.

The key distinctive feature in all of Unilife's safety syringes is that the operator may control the speed of automatic needle retraction within a fully integrated safety syringe. This novel combination of safety features, which Unilife does not believe is available with any other technology on the market today, can virtually eliminate the risk of acquiring bloodborne infections, such as the human immunodeficiency virus (HIV) or hepatitis C, via needlestick injuries or aerosol (blood splatter).

In July 2008, sanofi-aventis SA (SNY-NYSE) -- the world's fourth largest pharmaceutical group and largest purchaser of prefilled syringes -- signed an Exclusive Agreement with Unilife, under which sanofi-aventis paid $13.9 million (euro 10 million) for the right to purchase the Unilife Prefilled Syringe for five years. Sanofi-aventis is
'/>"/>